Literature DB >> 22923039

[Anxiety and depression in cancer patients during the course of radiotherapy treatment].

J Maurer1, C Schäfer, O Maurer, O Kölbl.   

Abstract

BACKGROUND: Undergoing radiotherapy is often associated with severe impairment of quality of life in cancer patients. Especially psychosocial aspects like anxiety and depression play a major role. The aim of this study was to closely analyze anxiety and depression during the course of radiotherapy treatment.
METHODS: A total of 60 patients, who received radiotherapy because of a tumor disease between June 2005 and April 2006, were included in the prospective study; 57 (95%) patients were primarily treated with radiotherapy. In 72% of the cases the intention to treat was curable, in 18% palliative. Anxiety and depression (HADS-D) were assessed at three points in time: before (A) and after (B) radiotherapy treatment (RT), and 6 weeks after finishing RT at the follow-up appointment (C).
RESULTS: Before therapy (A), 41% of the treated patients showed positive or marginally positive symptoms of anxiety and 33% symptoms of depression. The symptoms of anxiety significantly decreased during the course of therapy. The proportion of patients with a positive score of anxiety dropped from 16% at the beginning of RT (A) to 9% after the RT (B; p = 0.04). In addition, there was an increase in the number of patients who scored negatively with regard to anxiety from 59% (A) to 72% (B; p = 0.04). With regard to the median score of anxiety, no statistically significant change (p > 0.05) was observed during therapy, while for depression, the number of positively tested patients also decreased significantly during the course of therapy from the beginning of RT (A, 14%) to the first follow-up appointment (C, 9%; p = 0.02). Furthermore, the number of negatively tested patients rose by 8% (p = 0.02). During the whole course of the study, the median score of depression decreased from 6 (A) to 5 points (C; p = 0.01).
CONCLUSION: More than one third of the treated patients suffered from positive or marginally positive symptoms of anxiety and depression. This present study showed a decrease of anxiety and depression symptoms during the course of radiotherapy.

Entities:  

Mesh:

Year:  2012        PMID: 22923039     DOI: 10.1007/s00066-012-0143-y

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  22 in total

1.  Deterioration in quality of life and depressive symptoms during radiation therapy for head and neck cancer.

Authors:  Charles Kelly; Vinidh Paleri; Carole Downs; Raina Shah
Journal:  Otolaryngol Head Neck Surg       Date:  2007-01       Impact factor: 3.497

2.  Emotional state of patients in radiotherapy and how they deal with their disorder.

Authors:  Kristina Voigtmann; Volker Köllner; Franziska Einsle; Horst Alheit; Peter Joraschky; Thomas Herrmann
Journal:  Strahlenther Onkol       Date:  2010-03-26       Impact factor: 3.621

3.  Dysphagia. Impact on quality of life after radio(chemo)therapy of head and neck cancer.

Authors:  Julia Maurer; Matthias Hipp; Christof Schäfer; Oliver Kölbl
Journal:  Strahlenther Onkol       Date:  2011-10-28       Impact factor: 3.621

4.  Patient information in radiooncology results of a patient survey.

Authors:  Christof Schäfer; Barbara Dietl; Kurt Putnik; Daniel Altmann; Jörg Marienhagen; Manfred Herbst
Journal:  Strahlenther Onkol       Date:  2002-10       Impact factor: 3.621

5.  [Comorbid psychiatric disorders in cancer patients in acute inpatient treatment and medical rehabilitation].

Authors:  M Härter; K Reuter; B Schretzmann; A Hasenburg; A Aschenbrenner; J Weis
Journal:  Rehabilitation (Stuttg)       Date:  2000-12       Impact factor: 1.113

6.  Increased incidence of affective disorders, anxiety disorders, and non-natural mortality in women after breast cancer diagnosis: a nation-wide cohort study in Denmark.

Authors:  K Hjerl; E W Andersen; N Keiding; P B Mortensen; T Jørgensen
Journal:  Acta Psychiatr Scand       Date:  2002-04       Impact factor: 6.392

7.  Normative data for the HADS from a large non-clinical sample.

Authors:  J R Crawford; J D Henry; C Crombie; E P Taylor
Journal:  Br J Clin Psychol       Date:  2001-11

8.  Relevance of philosophy of life and optimism for psychological distress among individuals in a stage where death is approaching.

Authors:  Jeanette Winterling; Elisabet Wasteson; Birgitta Sidenvall; Erik Sidenvall; Bengt Glimelius; Per-Olow Sjödén; Karin Nordin
Journal:  Support Care Cancer       Date:  2005-08-03       Impact factor: 3.603

9.  The hospital anxiety and depression scale.

Authors:  A S Zigmond; R P Snaith
Journal:  Acta Psychiatr Scand       Date:  1983-06       Impact factor: 6.392

10.  Psychiatric disorder in patients with advanced breast cancer: prevalence and associated factors.

Authors:  K L Pinder; A J Ramírez; M E Black; M A Richards; W M Gregory; R D Rubens
Journal:  Eur J Cancer       Date:  1993       Impact factor: 9.162

View more
  9 in total

1.  [Effect of systematic information about psychosocial support services during outpatient radiotherapy. A controlled trial].

Authors:  R O Schiel; W Herzog; H Hof; J Debus; H-C Friederich; A Brechtel; J Rummel; P Freytag; M Hartmann
Journal:  Strahlenther Onkol       Date:  2013-06-09       Impact factor: 3.621

2.  Patient's quality of life after high-dose radiation therapy for thoracic carcinomas : Changes over time and influence on clinical outcome.

Authors:  Christina Schröder; Rita Engenhart-Cabillic; Hilke Vorwerk; Michael Schmidt; Winfried Huhnt; Eyck Blank; Dietrich Sidow; André Buchali
Journal:  Strahlenther Onkol       Date:  2016-10-27       Impact factor: 3.621

3.  Augmented Reality in Radiology for Education and Training-A Design Study.

Authors:  Alexander Raith; Christoph Kamp; Christina Stoiber; Andreas Jakl; Markus Wagner
Journal:  Healthcare (Basel)       Date:  2022-04-02

4.  Physical and psychosocial support requirements of 1,500 patients starting radiotherapy.

Authors:  K Kirchheiner; A Czajka; E Ponocny-Seliger; C Lütgendorf-Caucig; M P Schmid; E Komarek; R Pötter; W Dörr
Journal:  Strahlenther Onkol       Date:  2013-03-29       Impact factor: 3.621

5.  Validation and practical implementation of a multidisciplinary cancer distress screening questionnaire.

Authors:  K Kirchheiner; A Czajka; E Ponocny-Seliger; E Komarek; G Hohenberg; R Pötter; W Dörr
Journal:  Strahlenther Onkol       Date:  2013-05-25       Impact factor: 3.621

6.  Patient-reported symptoms during radiotherapy : Clinically relevant symptom burden in patients treated with palliative and curative intent.

Authors:  Philipp Körner; Katja Ehrmann; Johann Hartmannsgruber; Michaela Metz; Sabrina Steigerwald; Michael Flentje; Birgitt van Oorschot
Journal:  Strahlenther Onkol       Date:  2017-06-01       Impact factor: 3.621

7.  Assessing cancer patients' quality of life and supportive care needs: Translation-revalidation of the CARES in Flemish and exhaustive evaluation of concurrent validity.

Authors:  Bojoura Schouten; Elke Van Hoof; Patrick Vankrunkelsven; Ward Schrooten; Paul Bulens; Frank Buntinx; Jeroen Mebis; Dominique Vandijck; Irina Cleemput; Johan Hellings
Journal:  BMC Health Serv Res       Date:  2016-03-11       Impact factor: 2.655

8.  Using the revised Edmonton symptom assessment scale during neoadjuvant radiotherapy for retroperitoneal sarcoma.

Authors:  Russell F Palm; Heather S L Jim; David Boulware; Peter A S Johnstone; Arash O Naghavi
Journal:  Clin Transl Radiat Oncol       Date:  2020-02-28

9.  Whole-brain irradiation with hippocampal sparing and dose escalation on metastases: neurocognitive testing and biological imaging (HIPPORAD) - a phase II prospective randomized multicenter trial (NOA-14, ARO 2015-3, DKTK-ROG).

Authors:  Anca-Ligia Grosu; Lars Frings; Iryna Bentsalo; Oliver Oehlke; Franziska Brenner; Angelika Bilger; Jamina Tara Fennell; Thomas Rothe; Sabine Schneider-Fuchs; Erika Graf; Claudia Schmoor; Jürgen Beck; Gerhild Becker; Michael Bock; Karl Egger; Horst Urbach; Claas Lahmann; Ilinca Popp
Journal:  BMC Cancer       Date:  2020-06-08       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.